The global Human Gene Therapy market size is predicted to grow from US$ 5868 million in 2025 to US$ 8579 million in 2031; it is expected to grow at a CAGR of 6.5% from 2025 to 2031.

Gene therapy isa medical approach that treats or prevents disease by correcting the underlying genetic problem. Gene therapy techniques allow doctors to treat a disorder by altering a persons genetic makeup instead of using drugs or surgery.

Advances in gene therapy technology, increasing understanding of genetics, and the potential for addressing previously untreatable diseases contribute to the growth of the Human Gene Therapy market.

Infinity Market Research newest research report, the ?Human Gene Therapy Industry Forecast? looks at past sales and reviews total world Human Gene Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Gene Therapy sales for 2025 through 2031. With Human Gene Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Gene Therapy industry.

This Insight Report provides a comprehensive analysis of the global Human Gene Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Gene Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Human Gene Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Gene Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Gene Therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Human Gene Therapy market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Non-viral Vectors
    Viral Vectors

Segmentation by Application:

    Neurological Diseases
    Cancer
    DMD (Duchenne Muscular Dystrophy)
    Hepatological Diseases
    Others

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Biogen
    Sarepta Therapeutics
    Gilead Sciences
    Amgen
    Novartis
    Orchard Therapeutics
    Spark Therapeutics
    Agc Biologics
    Anges
    Bluebird Bio
    Jazz Pharmaceuticals
    Dynavax Technologies
    Human Stem Cells Institute
    Sibiono Genetech
    Shanghai Sunway Biotech
    Uniqure N.V.
    Gensight Biologics S.A.
    Celgene Corporation
    Cellectis
    Sangamo Therapeutics
    Mustang Bio
    AGTC
    Poseida Therapeutics

Key Questions Addressed in this Report

What is the 10-year outlook for the global Human Gene Therapy market?
What factors are driving Human Gene Therapy market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Gene Therapy market opportunities vary by end market size?
How does Human Gene Therapy break out by Type, by Application?